Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.74 |
| ▸ | NAAA | Q02083 | 1/20 | 0.66 |
| ▸ | DGKA | P23743 | 1/20 | 0.60 |
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 8/20 | 0.55 |
| ▸ | THRA | P10827 | 8/20 | 0.55 |
| ▸ | RAD52 | P43351 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.51 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.51 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16154783 | 0.92 | DNM1 (0.68) | DNM1NAAADGKAHTR2CTHRB | |
| SCHEMBL1671498 | 0.91 | DNM1 (0.77) | DNM1NAAADGKAHTR2CTHRB | |
| SCHEMBL20684164 | 0.91 | DNM1 (0.77) | DNM1NAAADGKAHTR2CTHRB | |
| SCHEMBL18632645 | 0.89 | DNM1 (0.81) | DNM1NAAADGKAHTR2CTHRB | |
| SCHEMBL7898793 | 0.89 | DNM1 (0.81) | DNM1NAAADGKAHTR2CTHRB | |
| SCHEMBL7890298 | 0.89 | DNM1 (0.81) | DNM1NAAADGKAHTR2CTHRB | |
| SCHEMBL11577809 | 0.89 | DNM1 (0.81) | DNM1NAAADGKAHTR2CTHRB | |
| SCHEMBL7898648 | 0.89 | DNM1 (0.81) | DNM1NAAADGKAHTR2CTHRB | |
| SCHEMBL7898266 | 0.89 | DNM1 (0.81) | DNM1NAAADGKAHTR2CTHRB | |
| SCHEMBL21226019 | 0.89 | DNM1 (0.81) | DNM1NAAADGKAHTR2CTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116549389-A | Intranasal adrenergic formulations and methods of treating diseases | 爱奇司治疗公司 | 2023-08-08 | — | — | CN | disclosed |
| CN-110505873-B | Intranasal epinephrine formulations and methods of treating disease | 爱奇司治疗公司 | 2022-12-30 | — | — | CN | disclosed |
| CN-113329758-A | Transferrin receptor targeting peptides | 弗莱德哈钦森癌症研究中心 | 2021-08-31 | — | — | CN | disclosed |
| US-20050032900-A1 | Ibuprofen salt emulsifiers and cream formulations containing same | MACROCHEM CORPORATION | 2005-02-10 | — | — | US | disclosed |
| EP-1432405-A1 | IBUPROFEN SALT EMULSIFIERS AND CREAM FORMULATIONS CONTAINING SAME | MacroChem Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003028702-A1 | IBUPROFEN SALT EMULSIFIERS AND CREAM FORMULATIONS CONTAINING SAME | MACROCHEM CORPORATION (US) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032900-A1 | Ibuprofen salt emulsifiers and cream formulations containing same | ALOX12, NAPEPLD, ACMSD | DNM1 3534/4885NAAA 465/4885DGKA 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.